Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood platelets may hold key to faster ALS diagnosis

NCT ID NCT07479017

Diagnosis Sponsor: University Hospital, Tours Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to find specific markers in blood platelets that can help doctors diagnose ALS (Lou Gehrig's disease) more accurately and earlier. Researchers will compare 60 participants—30 with newly diagnosed ALS and 30 with other motor neuron diseases—to see if platelet tests can tell them apart. The goal is to develop a routine blood test that speeds up diagnosis and treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with ALS or another MND followed in 3 ALS centers

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients with ALS: * Men or women aged 18 to 75 * ALS diagnosed according to the El Escorial criteria * ALS diagnosis less than 3 months ago * Onset of symptoms defined as the time when muscle weakness was first observed by the patient less than 2 years ago Controls with another motor neuron disease: * Men or women aged 18 to 75 * Diagnosis of motor neuron disease \< 3 months Exclusion Criteria: * Genetic variants associated with ALS * Pregnant or breastfeeding women * Treatment with oral or injectable anticoagulants, antiplatelet agents (EXCEPT aspirin at the maximum authorized dosage of 160 mg per day) * Uncontrolled diabetes * Persons deprived of their liberty by judicial or administrative decision * Persons subject to legal protection measures: guardianship or curatorship * Opposition to data processing

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALS (amyotrophic lateral sclerosis) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALS (amyotrophic lateral sclerosis)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University hospital, Limoges

    Limoges, 87000, France

  • University hospital, Lyon

    Lyon, 69000, France

  • university hospital, Tours

    Tours, 37044, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.